CABALETTA BIO INC (CABA)
US12674W1099 - Common Stock
ChartMill assigns a Buy % Consensus number of 83% to CABA. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 20.2. This target is 32.87% above the current price.
CABA was analyzed by 12 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about CABA.
In the previous month the buy percentage consensus was at a similar level.
CABA was analyzed by 12 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2023-09-18 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2023-09-05 | Citigroup | Initiate | Buy |
| 2023-08-14 | Guggenheim | Reiterate | Buy -> Buy |
| 2023-08-11 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-07-18 | Guggenheim | Initiate | Buy |
| 2023-05-17 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-05-12 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-05-03 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-04-10 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-04-03 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-03-22 | Chardan Capital | Reiterate | Buy |
| 2023-03-17 | Mizuho | Reiterate | Buy |
| 2023-03-17 | HC Wainwright & Co. | Maintains | Buy |
| 2023-02-17 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-01-27 | Morgan Stanley | Upgrade | Equal-Weight -> Overweight |
| 2023-01-03 | Wells Fargo | Maintains | Overweight |
| 2022-11-11 | Chardan Capital | Maintains | Buy |
| 2022-09-14 | Wells Fargo | Maintains | Overweight |
| 2022-08-30 | Morgan Stanley | Downgrade | Overweight -> Equal-Weight |
| 2022-08-12 | Chardan Capital | Maintains | Buy |
| 2022-05-25 | Mizuho | Maintains | Buy |
| 2021-12-15 | Morgan Stanley | Maintains | Overweight |
| 2021-12-08 | Wells Fargo | Initiate | Overweight |
| 2021-06-30 | Mizuho | Initiate | Buy |
| 2021-03-17 | HC Wainwright & Co. | Maintains | Buy |